Show simple item record

AuthorMellert, Kevindc.contributor.author
Date of accession2016-03-15T09:09:16Zdc.date.accessioned
Available in OPARU since2016-03-15T09:09:16Zdc.date.available
Year of creation2013dc.date.created
AbstractEnzyme replacement therapies have been performed since the 1970s to treat the lack of proteins in human blood or in lysosomes of human cells. Up to now, there are no comparable treatments to replace lacking proteins in the cytosol of cells of patients suffering from genetic diseases. Here, this approach is exemplarily studied in fibroblasts of neurofibromatosis type 1 (NF1) patients. In these cells, the amount of the cytosolic neurofibromin is reduced. This protein reduction leads to a hyperactivation of the mitogen activated protein kinase pathway and to an altered capability of the fibroblasts to orientate themselves on nanostructured surfaces. In cell cultures it could be shown that the missing amounts of neurofibromin in NF1 haploinsufficient fibroblasts can be replaced using protein transduction methods. Two test systems were used to illustrate that the transduced neurofibromin can assume the functions of the lacking proteins in these cells and revert cellular effects based on NF1 haploinsufficiency. The endolysosomal entrapment of transduced proteins is the bottleneck of cytosolic protein transduction. For the cell culture experiments, this problem was solved by performing photochemical internalization (PCI) treatments. PCI was used to translocate endosomal entrapped proteins to the cytosol of the transduced fibroblasts. For that systemic PCI treatments are not realizable in patients, future studies will have to examine protein modifications that allow a cytosolic delivery of transduced proteins without an interfering from an external source. Experiments using a neurofibromin fused to the protein transduction domain of HIV-TAT revealed promising evidence that modifications can replace secondary treatments like PCI. Hence, the cytosolic replacement of lacking intracellular proteins seems to be a possible treatment for patients with monogenic diseases like NF1.dc.description.abstract
Languagededc.language.iso
PublisherUniversität Ulmdc.publisher
LicenseStandard (ohne Print-On-Demand)dc.rights
Link to license texthttps://oparu.uni-ulm.de/xmlui/license_opod_v1dc.rights.uri
KeywordNano-structured surfacedc.subject
KeywordPhotochemical internalizationdc.subject
KeywordProtein replacement therapydc.subject
KeywordProtein uptakedc.subject
Dewey Decimal GroupDDC 610 / Medicine & healthdc.subject.ddc
MeSHCell-penetrating peptidesdc.subject.mesh
MeSHEnzyme replacement therapy; Methodsdc.subject.mesh
MeSHNeurofibromatosisdc.subject.mesh
TitleRevertierung von Neurofibromatose Typ 1 Haploinsuffizienzeffekten durch Proteintransduktion in vitrodc.title
Resource typeDissertationdc.type
DOIhttp://dx.doi.org/10.18725/OPARU-3088dc.identifier.doi
PPN850941539dc.identifier.ppn
URNhttp://nbn-resolving.de/urn:nbn:de:bsz:289-vts-89360dc.identifier.urn
GNDEnzymtherapiedc.subject.gnd
GNDNeurofibromatosedc.subject.gnd
GNDTyp 1dc.subject.gnd
FacultyMedizinische Fakultätuulm.affiliationGeneral
Date of activation2014-03-12T13:10:23Zuulm.freischaltungVTS
Peer reviewneinuulm.peerReview
Shelfmark print versionW: W-H 14.605uulm.shelfmark
DCMI TypeTextuulm.typeDCMI
VTS-ID8936uulm.vtsID
CategoryPublikationenuulm.category
University Bibliographyjauulm.unibibliographie


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record